Shenglin Mei, Ph.D.
"By advancing our understanding of malignant cell heterogeneity and tumor microenvironment remodeling, we aim to drive the development of novel therapeutic approaches for patients with metastatic cancer."
Examining the tumor microenvironment during metastatic cascade
How can computational methods help predict, detect, and treat metastatic cancer?
With a background in statistics and bioinformatics, Shenglin Mei studies remodeling and regulation of the tumor microenvironment as cancer cells migrate from the primary tumor to another location in the body. This process, known as metastasis, is responsible for the majority of cancer-related deaths.
Dr. Mei applies a combination of computational biology, genetics, and immunology approaches to the study of cancer. Leveraging single-cell sequencing and spatial transcriptomics techniques to analyze large-scale genomic data, he investigates the molecular drivers of tumor progression. His research is aimed identifying biomarkers for metastasis, driving early detection, and developing new therapies by studying not just tumors themselves, but also the supporting cellular components, signaling networks, and metabolic interactions that could be key to slowing and stopping disease progression.
shenglinmei@vt.edu
Children's National Research & Innovation Campus in Washington, D.C.
- Assistant Professor, Fralin Biomedical Research Institute at VTC
- Assistant Professor, Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine
Mei, S., Alchahin, A. M., Embaie, B. T. et al. Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature. JCI insight, 9(6), e173337 (2024). https://doi.org/10.1172/jci.insight.173337
Mei, S., Alchahin, A. M., Tsea, I. et al. Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions. Genome medicine, 16(1), 1 (2024). https://doi.org/10.1186/s13073-023-01272-6
Hirz, T., Mei, S., Sarkar, H. et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun 14, 663 (2023). https://doi.org/10.1038/s41467-023-36325-2
Alchahin, A.M., Mei, S., Tsea, I. et al. A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma. Nat Commun 13, 5747 (2022). https://doi.org/10.1038/s41467-022-33375-w
Kfoury, Y., Baryawno, N., Severe, N., Mei, S. et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer cell, 39(11), 1464–1478.e8 (2021). https://doi.org/10.1016/j.ccell.2021.09.005
Massachusetts General Hospital, Harvard Medical School, Instructor
Massachusetts General Hospital, Research Fellow
Harvard Medical School, Postdoctoral Fellow
Dana Farber Cancer Institute, Harvard University, Research Assistant
- Tongji University, Ph.D., Bioinformatics
- Harvard T.H. Chan School of Public Health, Visiting Scholar
- Nanjing Agricultural University, B.S., Statistics
- Young Investigator Award, Royalty Pharma-Prostate Cancer Foundation, (2023-2026)
- Challenge Award, Michael & Lori Milken Family Foundation-Prostate Cancer Foundation (2022-2025)
- Outstanding Graduates Award, Nanjing Agricultural University (2012)